The RAGE-NFκB axis precisely controls SHP-2 expression in T2DM conditions, and the pharmacological and genetic targeting of this upstream signalling axis was sufficient to blunt SHP-2 expression and attenuate SHP-2-induced monocyte activation. The gene discussed is NFKB1; the disease is type 2 diabetes mellitus.